report that CAR Tcell activity against solid tumors depends on cell adhesion mediated by IFN纬 signaling, opening the prospect of improving their clinical activity in the future.doi:10.1016/j.medj.2022.05.009Matthew.BellDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude ...
Relapsed/refractory peripheral T cell lymphomas (PTCLs) are aggressive tumors with a poor prognosis. Unlike B cell lymphomas, treatment of PTCL has not benefited from advances in immunotherapy. This is largely due to a lack of suitable target antigens th
Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of cellular therapies for all patients is needed. Manufacture of patient-derived CAR T cells is li...
along with Professor XIAO Gang and QIAN Pengxu from Zhejiang University School of Medicine, collaborated on a research paper published inCell Metabolismtitled "Mitochondrial isocitrate dehydrogenase impedes CAR T-cell function by ...
Chimeric antigen receptor (CAR) T cell therapies have evolved from a research tool to a concept-shifting therapy with impressive responses in B cell malignancies. This Review summarizes the current state of the CAR T cell field, focusing on CD19- and B cell maturation antigen-directed CAR T ...
“Natural T-cell function isn’t good enough. We need to explore theextremes of T-cell function,” says Kole Roybal, animmunologistat the University of California, San Francisco, and co-author of the new paper. What better place to start than with the mutations that turn healthy T cells...
The use of CAR-T cells in the therapy of relapsed and refractory B-type acute lymphoblastic leukemia (ALL) resulted in complete remission in many ... J Zarychta,A Kowalczyk,M Krawczyk,... - 《Cancers》 被引量: 0发表: 2023年 Targeted therapy and immunotherapy for T cell acute lymphoblasti...
‹CAR T Cell Therapy Research CAR T Cell and Other Adoptive Cell Therapy Workflows 5 steps to adoptive T cell therapy Adoptive cell therapy (ACT) has emerged as an effective approach in immuno-oncology research. In recent yea...
Interviewer: OK, thank you. We know that the initial CAR-T cell therapy is mainly used in blood tumors and has achieved good results, but the treatment of solid tumors is still under research. Do you think the effect of CAR-...
However, these CAR-T cells could not produce enough interleukin-2 (IL-2), so in order to kill tumor cells it was necessary to administer exogenous IL-2. Therefore, the first generation of CAR-T cell therapy transfected with single-chain receptors benefitted substantially from the accompanying...